1. Home
  2. EGY vs OMER Comparison

EGY vs OMER Comparison

Compare EGY & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EGY
  • OMER
  • Stock Information
  • Founded
  • EGY 1985
  • OMER 1994
  • Country
  • EGY United States
  • OMER United States
  • Employees
  • EGY N/A
  • OMER N/A
  • Industry
  • EGY Oil & Gas Production
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • EGY Energy
  • OMER Health Care
  • Exchange
  • EGY Nasdaq
  • OMER Nasdaq
  • Market Cap
  • EGY 340.3M
  • OMER 397.1M
  • IPO Year
  • EGY N/A
  • OMER 2009
  • Fundamental
  • Price
  • EGY $3.84
  • OMER $3.21
  • Analyst Decision
  • EGY
  • OMER Strong Buy
  • Analyst Count
  • EGY 0
  • OMER 5
  • Target Price
  • EGY N/A
  • OMER $18.00
  • AVG Volume (30 Days)
  • EGY 1.1M
  • OMER 808.8K
  • Earning Date
  • EGY 08-05-2025
  • OMER 08-06-2025
  • Dividend Yield
  • EGY 6.53%
  • OMER N/A
  • EPS Growth
  • EGY N/A
  • OMER N/A
  • EPS
  • EGY 0.56
  • OMER N/A
  • Revenue
  • EGY $489,162,000.00
  • OMER N/A
  • Revenue This Year
  • EGY N/A
  • OMER N/A
  • Revenue Next Year
  • EGY $24.62
  • OMER $468.75
  • P/E Ratio
  • EGY $6.89
  • OMER N/A
  • Revenue Growth
  • EGY 3.02
  • OMER N/A
  • 52 Week Low
  • EGY $3.00
  • OMER $2.97
  • 52 Week High
  • EGY $7.43
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • EGY 64.80
  • OMER 34.64
  • Support Level
  • EGY $3.30
  • OMER $2.97
  • Resistance Level
  • EGY $4.04
  • OMER $4.06
  • Average True Range (ATR)
  • EGY 0.15
  • OMER 0.26
  • MACD
  • EGY 0.05
  • OMER 0.10
  • Stochastic Oscillator
  • EGY 81.66
  • OMER 22.02

About EGY VAALCO Energy Inc.

VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea, and Cote d'Ivoire. The company generates maximum revenue from the Gabon segment.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: